Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 30Recruiting 26Unknown 23Active not recruiting 23Terminated 15Withdrawn 13Not yet recruiting 4

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gynecologic 1CNS 1Breast 1

Conditions

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers 1Glioma 1Efficacy 1Advanced Ovarian Cancer 1

Interventions

Drug Therapy 107Cisplatin 97Radiotherapy 89Carboplatin 87Bevacizumab 79Oxaliplatin 74tislelizumab 68Capecitabine 68Gemcitabine 64Cyclophosphamide 64toripalimab 62Paclitaxel 57pembrolizumab 55sintilimab 53Specimen Handling 53Surgical Procedures, Operative 52anlotinib 49Fluorouracil 49Magnetic Resonance Spectroscopy 48Immune Checkpoint Inhibitors 43Blood Specimen Collection 42130-nm albumin-bound paclitaxel 42Standard of Care 38camrelizumab 36fludarabine 35lenvatinib 34Leucovorin 34venetoclax 30Radiosurgery 30Immunotherapy 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × niraparib × Clear all
NCT07059676 2025-07-11

LIBINI-1

Clinica Universidad de Navarra, Universidad de Navarra

Not yet recruiting
120 enrolled
Gynecologic

Advanced Ovarian Cancer

NCT06258018 2024-08-30

ONC-2022-001

Istituto Clinico Humanitas

Phase 1/2 Not yet recruiting
86 enrolled
CNS

Glioma

NCT06237205 2024-02-01

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Korea University Anam Hospital

Phase 2 Not yet recruiting
33 enrolled

Efficacy

NCT05232006 2022-03-08

PALB2-PARPi-01

Assistance Publique - Hôpitaux de Paris

Phase 2 Not yet recruiting
12 enrolled
Breast

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡